FDA 483 OBSERVATION · #839 OF 1,932 MOST-CITED
Reasonably foreseeable risks or discomforts
FDA cited this observation 23 times across 23 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
How FDA worded it — real examples
The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.
The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.
The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.
The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.
The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.
The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →